1/8
07:00 am
vrdn
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
High
Report
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
1/7
08:04 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
12/19
08:10 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "equal weight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $27.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "equal weight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $27.00 price target on the stock.
12/17
10:31 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Royal Bank of Canada from $44.00 to $47.00. They now have an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Royal Bank of Canada from $44.00 to $47.00. They now have an "outperform" rating on the stock.
12/16
10:49 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
Medium
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
12/16
07:10 am
vrdn
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease [Yahoo! Finance]
Low
Report
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease [Yahoo! Finance]
12/16
07:00 am
vrdn
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
Low
Report
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
12/13
06:00 pm
vrdn
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
High
Report
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
12/5
11:14 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.
12/4
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/25
08:05 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Medium
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
11/25
08:02 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
11/19
09:04 am
vrdn
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]
Low
Report
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]
11/14
08:15 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at HC Wainwright from $27.00 to $34.00. They now have a "buy" rating on the stock.
Medium
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at HC Wainwright from $27.00 to $34.00. They now have a "buy" rating on the stock.
11/14
05:32 am
vrdn
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
11/13
08:06 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
11/12
07:00 am
vrdn
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
High
Report
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
11/5
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/28
08:25 am
vrdn
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Low
Report
Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.